BLLN

Billiontoone, Inc. Health Care Services-Medical Laboratories Russell 3000

$113.32Close $64.03 – $149.9752-week range Nov 4, 2026Next report · after the close

Highlights

Cautions

Results soon Nov 4, 2026, in 3 days

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Aug 5, 2026

Off 12-month high 24%

1wk 5.1% price change

1mo 6.5% price change

12-month return 4% total, dividends included

F-score — — Not assessed

Altman Z″ 7.37 Low risk

P/E — price / earnings

PEG — P/E / EPS growth

P/B — price / book

Earnings yield — EBIT / enterprise value

Cheaper than — of the market · not assessed

Revenue growth 100% year on year

EPS growth — latest quarter

Sales growth 64% latest quarter · -19 pts

ROE 2% return on equity

Free cash margin 5% $15.7M FCF

D/E 0.12 long-term debt / equity

Net debt / EBITDA -19.1× net cash

Interest cover —EBIT / interest

Piotroski tests

Repair signals

FCF turned positive ($-47M → $16M)
Gross margin 53.0% → 68.3%

Trade setup

ATR% 5.1% $5.83 a day · 2×ATR $101.65

RS — vs the universe

Trend — trend template

Relative volume 0.8× vs 50-day average

Up/down volume 0.89 50 sessions

Implied move — no option chain · report Nov 4, 2026

Screen verdict

Did not qualify for any screen.

Warning signs

none flagged

No restatement or impairment
Equity positive
Interest covered
No material dilution
Profits tracking cash
Margins and revenue not shrinking

Last reported Aug 5, 2026

Last shock Aug 6, 2026-39% in one session4.8× volumeon results+24% since

Financials

3 fiscal years · from filings

Revenue What customers paid the company over its fiscal year, before any cost, as filed in its annual report. The change is against the year before. Methodology $305.1M +100% on FY2024

Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology $7.5M back to a profit

Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology $15.7M back to a profit

Margins Each as a share of revenue. Gross: left after the direct cost of what was sold. Net: left after every cost. Free cash: free cash flow over revenue. A margin rising over years means the business keeps more of each dollar it sells. Methodology

Gross 68%
Net 2%
Free cash 5%

Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology $438.7M net cash

Cash
Long-term debt

	FY2023Dec 31, 2023	FY2024Dec 31, 2024	FY2025Dec 31, 2025
Revenue	$71.7M	$152.6M	$305.1M
Gross margin	24%	53%	68%
Operating income	-$69.5M	-$47.1M	$16.0M
Net income	-$82.7M	-$41.6M	$7.5M
Net margin	-115%	-27%	2%
Earnings per share	-$8.45	-$4.12	$0.35
Free cash flow	-$59.8M	-$46.8M	$15.7M
Free cash margin	-83%	-31%	5%
Cash	$97.3M	$191.5M	$496.0M
Long-term debt	—	$51.5M	$57.2M
Shareholders' equity	-$219.1M	-$251.7M	$480.1M
Shares outstanding	—	10.93m	—

Filings

SEC EDGAR

Filed	Report	Period to	Lag
Aug 5, 2026	Quarterly ↗	Jun 30, 2026	36d
May 6, 2026	Quarterly ↗	Mar 31, 2026	36d
Mar 11, 2026	Annual ↗	Dec 31, 2025	70d
Dec 10, 2025	Quarterly ↗	Sep 30, 2025	71d

Current reports

Filed	Disclosed
Aug 5, 2026	Results ↗
Jun 29, 2026	Material agreement · New obligation ↗
Jun 16, 2026	Material agreement · New obligation ↗
May 6, 2026	Results ↗
Mar 4, 2026	Results · Director or officer change ↗
Jan 12, 2026	Results · Regulation FD ↗
Dec 9, 2025	Results · Director or officer change ↗
Nov 10, 2025	Charter or bylaws · Other events ↗